Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
boston top stories
4
×
life sciences
national blog main
boston
national top stories
clinical trials
gene therapy
new york blog main
san diego blog main
san francisco blog main
startups
third rock ventures
20/20 healthcare partners
acetylon pharmaceuticals
ally bridge group
ambys medicines
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
cell therapy
christian angermayer
constellation pharmaceuticals
deals
diabetic nephropathy
dolby family ventures
duchenne muscular dystrophy
dyne therapeutics
enclear therapies
eventide asset management
facioscapulohumeral muscular dystrophy
What
diseases
4
×
medicines
new
biotech
develop
drug
genetic
ipo
raised
ago
aiming
ambys
analysis
associated
big
bio
biotechs
bring
companies
company
considering
control
data
deadly
deal
debuted
device
dialysis
disease
drugs
dyne
early
employing
enclear
expected
experimental
eyes
formed
future
goldfinch
Language
unset
Current search:
diseases
×
biotech
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?